Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 15/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.62 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.62 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284440 | 0.88 | CACNA1H (0.63) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL11716675 | 0.81 | CACNA1H (0.61) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL8872735 | 0.81 | CACNA1H (0.60) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL30822920 | 0.81 | CACNA1H (0.60) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL30822917 | 0.81 | CACNA1H (0.60) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL7002106 | 0.81 | RIPK1 (0.55) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL2418541 | 0.81 | CACNA1H (0.60) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL8264508 | 0.81 | CACNA1H (0.60) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 | |
| SCHEMBL8481047 | 0.81 | CSNK2A1 (0.43) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL6270528 | 0.77 | CACNA1H (0.41) | CACNA1HCACNA1CCACNA1BCACNA1GEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10734677-B2 | Substituted imidazole and benzimidazole lithium salts | ROBERT BOSCH GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| WO-2019005216-A1 | SUBSTITUTED IMIDAZOLE AND BENZIMIDAZOLE LITHIUM SALTS | SEEO, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10734677-B2 | Substituted imidazole and benzimidazole lithium salts | KCNJ11, KCNJ1, KCNJ8 | CACNA1H 339/4885CACNA1C 93/4885CACNA1B 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.